Based on these immune enhancing effects of classically activated macrophages, the GVAX cancer vaccine platform has been successful in several clinical trials involving administration of GM-CSF-secreting autologous tumor cells in that those results indicated enhanced anti-tumor immunity [40]. The gene discussed is CSF2; the disease is neoplasm.